The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound as the first pharmaceutical ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

This time last year, people were still bickering about whether Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound represented a shortcut to losing weight or a medical breakthrough.

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity, are no longer in shortage, The agency’s decision will ...

“This is a major step forward for patients with obstructive sleep apnea,” US Food and Drugs Administration (FDA) official Sally Seymour said in a statement announcing the approval of Zepbound ...

2017. Zepbound, an Eli Lilly drug, can now be prescribed to adults with “moderate-to-severe obstructive sleep apnea and obesity” to improve their sleep, a press release from the company said.

In a news release published Dec. 20, the FDA stated that Zepbound, part of the GLP-1 receptor agonist medicines that include Ozempic, was cleared to treat moderate to severe OSA in individuals ...

MONDAY, Dec. 23, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the ...